APA (7th ed.) Citation

Javle, M., Roychowdhury, S., Kelley, R. K., Sadeghi, S., Macarulla, T., Weiss, K. H., . . . Abou-Alfa, G. K. (2021). Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. The lancet. Gastroenterology & Hepatology, 6(10), . https://doi.org/10.1016/S2468-1253(21)00196-5

Chicago Style (17th ed.) Citation

Javle, Milind, et al. "Infigratinib (BGJ398) in Previously Treated Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Mature Results from a Multicentre, Open-label, Single-arm, Phase 2 Study." The Lancet. Gastroenterology & Hepatology 6, no. 10 (2021). https://doi.org/10.1016/S2468-1253(21)00196-5.

MLA (9th ed.) Citation

Javle, Milind, et al. "Infigratinib (BGJ398) in Previously Treated Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Mature Results from a Multicentre, Open-label, Single-arm, Phase 2 Study." The Lancet. Gastroenterology & Hepatology, vol. 6, no. 10, 2021, https://doi.org/10.1016/S2468-1253(21)00196-5.